Transforming The Management Of Critical Bleeding and Clotting

HemoSonics is bringing to market a next-generation point-of-care diagnostic platform, the Quantra, that provides actionable information to guide the management of critical bleeding and clotting.

Our goal is to improve outcomes and reduce healthcare costs by enabling more targeted selection and dosing of blood products in critical settings. We seek to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely and accurate information on coagulation status at the point of care, enabling clinicians to rapidly choose the right treatment, dramatically improving outcomes and lowering treatment costs.

Our Products

The Quantra™ is a rapid, easy-to-use, point-of-care diagnostic platform that fully characterizes and guides the management of critical bleeding.
Learn more.

Our Technology

Our patented SEER sonorheometry technology quantifies coagulation by measuring the evolving stiffness of clotting blood.
Learn more.

Our Leadership

Our team has a proven track record of successfully developing and bringing to market innovative medical devices.
Learn more.

Blood cells

Studies show that use of comprehensive point-of-care coagulation testing in surgical settings leads to:

Improved clinical outcomes

  • Fewer transfusions
  • Fewer complications

Reduced cost of care

  • Reduced blood product utilization
  • Shorter inpatient stays


Two Abstracts on SEER Technology to be Presented at IARS

Charlottesville, VA – May 19, 2016– HemoSonics today announced two upcoming presentations of data at the International Anesthesia Research Society (IARS) Annual Meeting May 21-24, 2016 in San Francisco, CA demonstrating the clinical utility of the Quantra™ Hemostasis Analyzer in monitoring patients undergoing cardiac and complex spine surgeries. The two studies conducted at the University of Virginia in Charlottesville, VA compared results obtained with research versions of the Quantra, a novel ultrasound-based device that uses Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry to measure the viscoelastic properties of blood, to equivalent rotational thromboelastometery (ROTEM™) and conventional laboratory parameters. The abstract “Comparison of SEER Sonorheometry with Rotational Thromboelastometry and Laboratory Parameters in Cardiac Surgery” authored by Dr. Julie Huffmyer and Dr. Danja Groves showed a strong correlation between Quantra and ROTEM parameters for clot stiffness and fibrinogen contribution in 55 patients undergoing elective cardiac surgery with cardiopulmonary bypass (CPB) (r=0.7-0.9). The Quantra platelet contribution, which reflects both platelet count and function, was well-correlated with the ROTEM platelet parameter but moderately correlated with the laboratory-determined platelet count, underscoring the limits of platelet count and the importance of a comprehensive measure of platelet function in the assessment of coagulation status in CPB patients whose platelet function may be compromised as a result of the procedure and preoperative anti-platelet therapy. Similarly, in the abstract “SEER Sonorheometry versus Rotational Thromboelastometry in Large Volume Blood Loss Spine Surgery”, Dr. Bhiken Naik and co-authors showed a strong correlation between Quantra and ROTEM for determining clot stiffness and assessing fibrinogen and platelet contribution to clot stiffness in 51 patients undergoing multi-level spine surgery. This abstract highlighted... read more

Comparison of SEER Technology to TEG in Cardiac Surgery Published in Anesthesia and Analgesia

Charlottesville, VA – May 10, 2016– HemoSonics today announced that a paper comparing its novel SEER technology to Thromboelastography (TEG) was published online in Anesthesia and Analgesia. The paper, A Comparison of a New Ultrasound-based Whole Blood Viscoelastic Test (SEER Sonorheometry) versus Thromboelastography (TEG) in Cardiac Surgery, describes the results of a study conducted at Virginia Commonwealth University in 50 cardiac surgery patients. The study compared the results of a research version of the Quantra™, a point-of-care in vitro diagnostic platform that measures blood clot formation and breakdown and provides actionable information to aid in the management of critical bleeding and clotting, with the TEG 5000 and standard laboratory tests. The study found that the Quantra results were significantly correlated with TEG measures of clot time (r=0.6-0.7) and clot stiffness (r=0.8-0.9) as well as standard laboratory tests for fibrinogen and platelet count (r=0.6-0.8). Complete Quantra results were available substantially faster than the TEG results (11 minutes vs 42 minutes, averages of Quantra vs TEG respectively), an important distinction in critical care settings where rapid treatment of bleeding is of the essence. The study substantiated the use of the Quantra’s Fibrinogen Contribution parameter, suggesting it may determine a more functional fibrinogen activity as compared to the TEG and conventional laboratory methods. In addition, the study showed a significant correlation between platelet count and the Quantra’s Platelet Contribution measure of platelet function (r=0.6-0.8), a parameter existing viscoelastic technologies do not measure. “Current viscoelastic testing is limited by long result times and incomplete parameter measures,” said Dr. Bruce Spiess, Professor and Associate Chief Anesthesiology (Research) at University of Florida and lead author of... read more

HemoSonics Opens New Facility in Durham, NC

Charlottesville, VA – December 7, 2015 – HemoSonics, a medical device company developing a point-of-care diagnostic platform to guide the management of critical bleeding, today announced that it has opened a new facility in Durham, NC. “The expertise in hemostasis in the Research Triangle is unparalleled, and we are excited to have a new facility that will leverage the wealth of talent in the region. This new facility will support the final stage of development and clinical testing of our Quantra™ platform,” said Tim Fischer, CEO of HemoSonics. “The university ecosystem provides ample sites for clinical testing and we have built out a strong team to fuel our future growth.” The Durham Facility currently has 11 employees. The facility will focus on software development, system engineering, reagent development, and clinical... read more

SEER Technology Published in Annals of Biomedical Engineering and to be Presented at IEEE International Ultrasonics Symposium

Charlottesville, VA – October 19, 2015 – HemoSonics, a medical device company developing and commercializing a point-of-care diagnostic platform to guide the management of critical bleeding, today announced that a paper detailing its novel SEER technology was published in the Annals of Biomedical Engineering. The paper, Sonic Estimation of Elasticity via Resonance: A New Method of Assessing Hemostasis, details the core technology behind the Quantra™, a point-of-care in vitro diagnostic platform that measures blood clot formation and breakdown and provides actionable information to guide the management of critical bleeding and clotting. SEER uses ultrasound to initiate and measure mechanical resonance in a clotting blood sample. The characteristics of this resonance are analyzed to precisely measure the evolving clot stiffness. SEER requires no moving parts and uses commodity electronics. An abstract detailing HemoSonics’ SEER technology was also accepted for the IEEE International Ultrasonics Symposium. The conference will be held in Taipei, Taiwan, on October 21-24th, 2015. Paper Citation Corey, FS, and WF Walker. “Sonic Estimation of Elasticity Via Resonance: A New Method of Assessing Hemostasis.” Annals of biomedical engineering (2015)doi:10.1007/s10439-015-1460-y. Abstract Details Title: Sonic Estimation of Elasticity via Resonance (SEER): Initial Results from a New Method of Assessing Hemostasis Authors: FS Corey, WF Walker Session: 3I – MEL: Towards clinical application of elasticity imaging Date: October 24, 2015, 10:30am –... read more